Paul David Johnson

Title: Paul David Johnson: Innovator in Protein Kinase B Inhibitors

Introduction

Paul David Johnson is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target protein kinase B (PKB). With a total of 6 patents to his name, Johnson's work is paving the way for new treatments in the medical field.

Latest Patents

Johnson's latest patents focus on a novel group of compounds that serve as protein kinase B inhibitors. These compounds, described by a specific formula, have potential applications in the treatment or prevention of diseases mediated through PKB, such as cancer. The patents also cover pharmaceutical compositions that include these compounds, methods of treatment for diseases mediated by PKB, and methods for preparing the compounds.

Career Highlights

Throughout his career, Johnson has been associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Johnson has collaborated with notable colleagues, including Andrew Leach and Richard William Arthur Luke. These collaborations have further enhanced the innovative work being done in the field of protein kinase inhibitors.

Conclusion

Paul David Johnson's contributions to the field of pharmaceuticals, particularly through his patents on protein kinase B inhibitors, highlight his role as a significant inventor. His work continues to influence the development of new medical treatments.